XOMA Corp CEO Sells $45,400 in Stock (XOMA)
XOMA Corp (NASDAQ:XOMA) CEO John Varian unloaded 10,000 shares of the company’s stock on the open market in a transaction dated Monday, June 16th. The stock was sold at an average price of $4.54, for a total value of $45,400.00. Following the transaction, the chief executive officer now directly owns 285,613 shares of the company’s stock, valued at approximately $1,296,683. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.
A number of analysts have recently weighed in on XOMA shares. Analysts at Wedbush raised their price target on shares of XOMA Corp to $14.00 in a research note on Monday, May 12th. They now have an “outperform” rating on the stock. Analysts at MLV & Co
upgraded shares of XOMA Corp from a “hold” rating to a “buy” rating in a research note on Tuesday, April 29th. They now have a $7.00 price target on the stock. They noted that the move was a valuation call. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and six have issued a buy rating to the company. The stock has a consensus rating of “Buy” and an average price target of $9.11.
XOMA Corp (NASDAQ:XOMA) opened at 4.86 on Friday. XOMA Corp has a 52 week low of $3.31 and a 52 week high of $9.57. The stock’s 50-day moving average is $4.20 and its 200-day moving average is $5.89. The company’s market cap is $519.5 million.
XOMA Corp (NASDAQ:XOMA) last announced its earnings results on Wednesday, May 7th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by $0.06. The company had revenue of $3.41 million for the quarter, compared to the consensus estimate of $7.40 million. During the same quarter in the previous year, the company posted ($0.30) earnings per share. The company’s revenue for the quarter was down 63.9% on a year-over-year basis. On average, analysts predict that XOMA Corp will post $-0.65 earnings per share for the current fiscal year.
XOMA Corporation (NASDAQ:XOMA) is engaged in the discovery and development of antibody-based therapeutics.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.